Valuation: Annexon, Inc.

Market Cap 895M 782M 719M 670M 1.27B 85.16B 1.29B 8.62B 3.35B 41.87B 3.36B 3.29B 144B P/E 2026 *
-5.82x
P/E 2027 * -6.97x
Enterprise Value 800M 700M 643M 599M 1.14B 76.17B 1.15B 7.71B 3B 37.44B 3B 2.94B 129B EV / Sales 2026 *
-
EV / Sales 2027 * 14.9x
Free-Float
93.57%
Yield 2026 *
-
Yield 2027 * -
1 day-1.62%
1 week-0.36%
Current month-4.38%
1 month+0.18%
3 months-0.73%
6 months+16.42%
Current year+8.76%
1 week 5.28
Extreme 5.275
6.04
1 month 4.46
Extreme 4.46
6.04
Current year 4.46
Extreme 4.46
7.18
1 year 1.85
Extreme 1.85
7.18
3 years 1.28
Extreme 1.285
8.4
5 years 1.28
Extreme 1.285
23.81
10 years 1.28
Extreme 1.285
38.01
Manager TitleAgeSince
Chief Executive Officer 58 2014-11-30
Director of Finance/CFO 53 2019-05-31
Chief Tech/Sci/R&D Officer 68 2023-07-26
Director TitleAgeSince
Director/Board Member 58 2014-11-30
Director/Board Member 65 2014-11-30
Director/Board Member 67 2021-02-04
Date Insider Type Main position Quantity % Market Cap.
06-10Free

Director

65,000 0.0397%
06-10Fiscal year

Chief Technology Officer

61,292 0.0374%
06-10Free

Director

65,000 0.0397%
Change 5-day change 1-year change 3-year change Capi.($)
-1.62%-0.36%+88.93%+58.26% 895M
+0.68%+5.92%+77.86%+139.22% 59.1B
+2.32%+5.03%+75.26%+91.40% 55.19B
+3.86%+6.93%-11.32%-9.53% 24.67B
+4.30%+7.95%+14.11%+437.83% 24.19B
+4.74%+13.68%+43.36%-4.67% 19.69B
-0.29%+9.78%+43.90%-28.41% 17.56B
0.00%+20.78%+186.15%+361.42% 16.22B
+6.72%+19.38%+37.85% - 14.84B
+3.50%+1.97%+21.02%+191.95% 14.04B
Average +2.42%+8.31%+57.71%+137.50% 24.64B
Weighted average by Cap. +2.45%+6.47%+58.44%+136.67%

Financials

2026 *2027 *
Net sales - 40.5M 35.42M 32.56M 30.34M 57.53M 3.86B 58.39M 390M 152M 1.9B 152M 149M 6.54B
Net income -188M -165M -151M -141M -268M -17.93B -272M -1.82B -706M -8.82B -707M -692M -30.42B -180M -157M -144M -135M -255M -17.1B -259M -1.73B -673M -8.41B -674M -660M -29B
Net Debt -94.47M -82.62M -75.95M -70.78M -134M -8.99B -136M -910M -354M -4.42B -355M -347M -15.26B -292M -255M -235M -219M -415M -27.79B -421M -2.81B -1.09B -13.66B -1.1B -1.07B -47.14B
Logo Annexon, Inc.
Annexon, Inc. is a clinical-stage biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. It identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology, using its proprietary platform. Its lead candidate, ANX005, an investigational, full-length monoclonal antibody (mAb), is formulated for intravenous administration as the potential first targeted treatment for patients with Guillain-Barre Syndrome (GBS). It is advancing ANX1502, a novel small-molecule inhibitor of classical complement designed for oral administration in a range of chronic autoimmune diseases. It is also advancing ANX007, designed to block C1q locally in the eye, to provide complete protection against excess classical complement activity and the loss of photoreceptor neurons.
Employees
93
Date Price Change Volume
26-07-02 US$5.460 -1.62% 2,561,838
26-07-01 US$5.550 -2.80% 4,919,969
26-06-30 US$5.710 +2.51% 3,633,748
26-06-29 US$5.570 +1.64% 8,568,150
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
5.460USD
Average target price
13.12USD
Spread / Average Target
+140.38%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ANNX Stock